Celgene Co. (CELG) Shares Sold by Telemus Capital LLC

Telemus Capital LLC lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 3.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 25,549 shares of the biopharmaceutical company’s stock after selling 983 shares during the period. Telemus Capital LLC owned 32.45% of Celgene worth $3,726,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of CELG. Grisanti Capital Management LLC bought a new stake in shares of Celgene during the second quarter worth approximately $3,616,000. RiverPoint Capital Management LLC boosted its holdings in shares of Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after acquiring an additional 3,680 shares during the period. Iguana Healthcare Management LLC boosted its holdings in shares of Celgene by 12.5% during the first quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock worth $11,199,000 after acquiring an additional 10,000 shares during the period. LSV Asset Management bought a new stake in shares of Celgene during the second quarter worth approximately $1,701,000. Finally, Spectrum Management Group Inc. bought a new stake in shares of Celgene during the second quarter worth approximately $462,000. Institutional investors and hedge funds own 79.74% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. Mizuho set a $128.00 price target on shares of Celgene and gave the company a “buy” rating in a research report on Friday. Stifel Nicolaus dropped their price target on shares of Celgene from $149.00 to $130.00 and set a “buy” rating for the company in a research report on Saturday, December 30th. SunTrust Banks set a $127.00 price target on shares of Celgene and gave the company a “buy” rating in a research report on Sunday, December 31st. Oppenheimer set a $166.00 price target on shares of Celgene and gave the company a “buy” rating in a research report on Thursday, December 28th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $162.00 price target on shares of Celgene in a research report on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and twenty have given a buy rating to the company’s stock. Celgene has an average rating of “Buy” and an average price target of $131.53.

Celgene Co. (NASDAQ:CELG) opened at $104.99 on Monday. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a market cap of $82,660.00, a P/E ratio of 24.76, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the business earned $1.58 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. equities research analysts anticipate that Celgene Co. will post 6.68 EPS for the current year.

WARNING: “Celgene Co. (CELG) Shares Sold by Telemus Capital LLC” was posted by Equities Focus and is owned by of Equities Focus. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.equitiesfocus.com/2018/01/08/celgene-co-celg-shares-sold-by-telemus-capital-llc.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply